Vini Louiza, Harmer Clive
Department of Clinical Oncology, Athens Medical Center, Greece.
Lancet Oncol. 2002 Jul;3(7):407-14. doi: 10.1016/s1470-2045(02)00787-8.
Thyroid cancers are a diverse group of malignant disorders ranging from indolent micropapillary carcinoma, which has no effect on life expectancy, to anaplastic tumours, which are invariably fatal even with aggressive treatment. Although the estimated incidence has increased by 14.6% over the past 40 years, the estimated death rate has fallen by 21%, probably as a result of earlier diagnosis. The natural history of thyroid tumours is no longer a mystery, and the prognostic factors identified can predict outcome fairly accurately. Improvements in management have mostly depended on information from large retrospective series, though there are still many areas open to debate. There has been, however, a general acceptance that thyroid cancer should be managed by multidisciplinary teams in specialised units following evidence-based guidelines.
甲状腺癌是一组多样的恶性疾病,从对预期寿命无影响的惰性微小乳头状癌到即使积极治疗也往往致命的未分化肿瘤。尽管在过去40年中估计发病率增加了14.6%,但估计死亡率下降了21%,这可能是早期诊断的结果。甲状腺肿瘤的自然病史已不再神秘,已确定的预后因素能够相当准确地预测结果。管理方面的改进大多依赖于大型回顾性系列研究提供的信息,不过仍有许多领域存在争议。然而,人们普遍接受甲状腺癌应由专业单位的多学科团队依据循证指南进行管理。